AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 0.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,866 shares of the company’s stock after purchasing an additional 164 shares during the period. Bryn Mawr Capital Management LLC’s holdings in AstraZeneca were worth $4,167,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. Private Trust Co. NA lifted its stake in shares of AstraZeneca by 41.0% in the third quarter. Private Trust Co. NA now owns 3,495 shares of the company’s stock valued at $237,000 after purchasing an additional 1,016 shares during the period. Caprock Group LLC lifted its holdings in shares of AstraZeneca by 2.4% in the third quarter. Caprock Group LLC now owns 11,107 shares of the company’s stock valued at $752,000 after purchasing an additional 262 shares in the last quarter. Koshinski Asset Management Inc. purchased a new stake in shares of AstraZeneca in the third quarter valued at about $444,000. Capital Asset Advisory Services LLC lifted its holdings in shares of AstraZeneca by 13.2% in the third quarter. Capital Asset Advisory Services LLC now owns 5,373 shares of the company’s stock valued at $365,000 after purchasing an additional 626 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of AstraZeneca by 7.2% in the third quarter. UMB Bank n.a. now owns 12,875 shares of the company’s stock valued at $872,000 after purchasing an additional 869 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.2 %

Shares of AZN stock traded up $0.14 on Friday, hitting $75.17. The stock had a trading volume of 6,687,806 shares, compared to its average volume of 6,265,456. The firm has a market capitalization of $233.06 billion, a price-to-earnings ratio of 39.15, a P/E/G ratio of 1.31 and a beta of 0.50. The stock’s 50 day moving average is $67.27 and its 200-day moving average is $66.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.64 and a current ratio of 0.82. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $75.81.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). AstraZeneca had a net margin of 13.00% and a return on equity of 30.19%. The company had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter last year, the company earned $0.69 earnings per share. The company’s revenue was up 7.3% compared to the same quarter last year. As a group, research analysts expect that AstraZeneca PLC will post 4 earnings per share for the current year.

AstraZeneca Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were given a $0.965 dividend. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a dividend yield of 2.3%. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is presently 100.52%.

Analysts Set New Price Targets

Several analysts have issued reports on AZN shares. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They issued an “overweight” rating for the company. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Finally, BMO Capital Markets boosted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.